Key facts
- This page summarizes Fairmount Funds Management LLC's Form 4 filing for Dianthus Therapeutics, Inc. /DE/ (DNTH).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 01 Oct 2024, 20:00.
Fairmount Funds Management LLC - 27 Sep 2024 Form 4 Insider Report for Dianthus Therapeutics, Inc. /DE/ (DNTH)
- Reporting relationship
- Director
- Issuer ticker
- DNTH
- Reported as of
- 27 Sep 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 01 Oct 2024, 20:00:12 UTC
- Prior SEC filing
- 17 Sep 2024
- Next SEC filing
- 21 Nov 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Tomas Kiselak, Managing Member of Fairmount Funds Management LLC
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Fairmount Funds Management LLC filed Form 4 for Dianthus Therapeutics, Inc. /DE/ (DNTH) on 01 Oct 2024.
Change
- Previous filing in this sequence was filed on 17 Sep 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
DNTH
transaction
Common Stock
Other
- Transaction value
- $0
- Shares
- -62,146
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 27 Sep 2024
- Ownership
- By Fairmount SPV III, LLC
- Footnotes
- F1, F2
DNTH
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 2,700,691
- Date
- 27 Sep 2024
- Ownership
- By Fairmount Healthcare Fund II L.P.
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents a pro rata distribution, and not a purchase or sale, without additional consideration by Fairmount SPV III, LLC ("Fairmount SPV") to its membership interest investors.
Footnote F2
Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. ("Fund II") and the Class A Member for Fairmount SPV. The general partner of Fairmount is Fairmount Funds Management GP LLC ("Fairmount GP"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
SEC remarks
Fairmount, Fund II and Fairmount SPV III, LLC may each be deemed a director by deputization of the Issuer by virtue of the fact that Tomas Kiselak serves on the board of directors of the Issuer and is a Managing Member of Fairmount.